Limits...
ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques.

Lemperle G, Knapp TR, Sadick NS, Lemperle SM - Aesthetic Plast Surg (2009)

Bottom Line: No serious side effects have been reported to date according to the FDA's MAUDE reporting database.The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction.This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

View Article: PubMed Central - PubMed

Affiliation: Division of Plastic Surgery, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103, USA. glemperle@aol.com

ABSTRACT
After more than 25 years of research and development, in October 2006 ArteFill became the first and only permanent injectable wrinkle filler to receive FDA approval. ArteFill is a third-generation polymeric microsphere-based filler, following its predecessor Artecoll, which was marketed outside the United States between 1994 and 2006. ArteFill is approved for the correction of nasolabial folds and has been used in over 15,000 patients since its U.S. market introduction in February 2007. No serious side effects have been reported to date according to the FDA's MAUDE reporting database. ArteFill consists of polymethylmethacrylate (PMMA) microspheres (20% by volume), 30-50 microm in diameter, suspended in 3.5% bovine collagen solution (80% by volume) and 0.3% lidocaine. The collagen carrier is absorbed within 1 month after injection and completely replaced by the patient's own connective tissue within 3 months. Each cc of ArteFill contains approximately six million microspheres and histological studies have shown that long-term wrinkle correction consists of 80% of the patient's own connective tissue and 20% microspheres. The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction. This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

Show MeSH

Related in: MedlinePlus

Human histology 10 years after Artecoll implantation shows mature connective tissue: active fibroblasts, microencapsulation of each single microsphere, capillary ingrowth, and little foreign body reaction (×40)
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2872009&req=5

Fig5: Human histology 10 years after Artecoll implantation shows mature connective tissue: active fibroblasts, microencapsulation of each single microsphere, capillary ingrowth, and little foreign body reaction (×40)

Mentions: Human histology after 10 years revealed strong bands of mature collagen fibers with fully intact capillary vasculature surrounding intact PMMA microspheres (which were dissolved by alcohol during histology processing) (Fig. 5). In essence, the ArteFill injection serves as a scaffold to promote a “living implant.” The PMMA components of ArteFill become fully integrated into the connective tissue, whether dermis or subdermal spaces. As in normal tissue with sufficient blood supply, there appears to be constant turnover of cells, including fibroblasts and macrophages.Fig. 5


ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques.

Lemperle G, Knapp TR, Sadick NS, Lemperle SM - Aesthetic Plast Surg (2009)

Human histology 10 years after Artecoll implantation shows mature connective tissue: active fibroblasts, microencapsulation of each single microsphere, capillary ingrowth, and little foreign body reaction (×40)
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2872009&req=5

Fig5: Human histology 10 years after Artecoll implantation shows mature connective tissue: active fibroblasts, microencapsulation of each single microsphere, capillary ingrowth, and little foreign body reaction (×40)
Mentions: Human histology after 10 years revealed strong bands of mature collagen fibers with fully intact capillary vasculature surrounding intact PMMA microspheres (which were dissolved by alcohol during histology processing) (Fig. 5). In essence, the ArteFill injection serves as a scaffold to promote a “living implant.” The PMMA components of ArteFill become fully integrated into the connective tissue, whether dermis or subdermal spaces. As in normal tissue with sufficient blood supply, there appears to be constant turnover of cells, including fibroblasts and macrophages.Fig. 5

Bottom Line: No serious side effects have been reported to date according to the FDA's MAUDE reporting database.The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction.This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

View Article: PubMed Central - PubMed

Affiliation: Division of Plastic Surgery, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103, USA. glemperle@aol.com

ABSTRACT
After more than 25 years of research and development, in October 2006 ArteFill became the first and only permanent injectable wrinkle filler to receive FDA approval. ArteFill is a third-generation polymeric microsphere-based filler, following its predecessor Artecoll, which was marketed outside the United States between 1994 and 2006. ArteFill is approved for the correction of nasolabial folds and has been used in over 15,000 patients since its U.S. market introduction in February 2007. No serious side effects have been reported to date according to the FDA's MAUDE reporting database. ArteFill consists of polymethylmethacrylate (PMMA) microspheres (20% by volume), 30-50 microm in diameter, suspended in 3.5% bovine collagen solution (80% by volume) and 0.3% lidocaine. The collagen carrier is absorbed within 1 month after injection and completely replaced by the patient's own connective tissue within 3 months. Each cc of ArteFill contains approximately six million microspheres and histological studies have shown that long-term wrinkle correction consists of 80% of the patient's own connective tissue and 20% microspheres. The standard injection technique is subdermal tunneling that delivers a strand of ArteFill at the dermal-subdermal junction. This strand beneath a wrinkle or fold acts like a support structure that protects against further wrinkling and allows the diminished thickness of the dermis to recover to its original thickness.

Show MeSH
Related in: MedlinePlus